![C7522967-B7A7-4574-BA71-426F01991739_1_201_a.jpeg?w=372&h=372&org_if_sml=0&optipress=2&fit_enlarge=1&sharp=0 C7522967-B7A7-4574-BA71-426F01991739_1_201_a.jpeg?w=372&h=372&org_if_sml=0&optipress=2&fit_enlarge=1&sharp=0](https://prosteps.cloudimg.io/v7/https://tilroy.s3.eu-west-1.amazonaws.com/108/content/C7522967-B7A7-4574-BA71-426F01991739_1_201_a.jpeg?w=372&h=372&org_if_sml=0&optipress=2&fit_enlarge=1&sharp=0)
C7522967-B7A7-4574-BA71-426F01991739_1_201_a.jpeg?w=372&h=372&org_if_sml=0&optipress=2&fit_enlarge=1&sharp=0
![1F9CA0AB-C76E-43DF-B768-DF7ACFB5BB96_1_201_a.jpeg?w=372&h=372&org_if_sml=0&optipress=2&fit_enlarge=1&sharp=0 1F9CA0AB-C76E-43DF-B768-DF7ACFB5BB96_1_201_a.jpeg?w=372&h=372&org_if_sml=0&optipress=2&fit_enlarge=1&sharp=0](https://prosteps.cloudimg.io/v7/https://tilroy.s3.eu-west-1.amazonaws.com/108/content/1F9CA0AB-C76E-43DF-B768-DF7ACFB5BB96_1_201_a.jpeg?w=372&h=372&org_if_sml=0&optipress=2&fit_enlarge=1&sharp=0)
1F9CA0AB-C76E-43DF-B768-DF7ACFB5BB96_1_201_a.jpeg?w=372&h=372&org_if_sml=0&optipress=2&fit_enlarge=1&sharp=0
![EB9611F1-0D4C-4D77-8BB8-0022E3EA5F48_1_201_a.jpeg?w=372&h=372&org_if_sml=0&optipress=2&fit_enlarge=1&sharp=0 EB9611F1-0D4C-4D77-8BB8-0022E3EA5F48_1_201_a.jpeg?w=372&h=372&org_if_sml=0&optipress=2&fit_enlarge=1&sharp=0](https://prosteps.cloudimg.io/v7/https://tilroy.s3.eu-west-1.amazonaws.com/108/content/EB9611F1-0D4C-4D77-8BB8-0022E3EA5F48_1_201_a.jpeg?w=372&h=372&org_if_sml=0&optipress=2&fit_enlarge=1&sharp=0)
EB9611F1-0D4C-4D77-8BB8-0022E3EA5F48_1_201_a.jpeg?w=372&h=372&org_if_sml=0&optipress=2&fit_enlarge=1&sharp=0
Einde van een tijdperk: Schoenen Timmermans verruilt gigantische zaak voor kleinere winkel in Stationsstraat en begint baanwinkel in Belsele | Sint-Niklaas | hln.be
![PDF) Erenumab for Migraine Prevention in a 1-Year Compassionate Use Program: Efficacy, Tolerability, and Differences Between Clinical Phenotypes PDF) Erenumab for Migraine Prevention in a 1-Year Compassionate Use Program: Efficacy, Tolerability, and Differences Between Clinical Phenotypes](https://i1.rgstatic.net/publication/356916412_Erenumab_for_Migraine_Prevention_in_a_1-Year_Compassionate_Use_Program_Efficacy_Tolerability_and_Differences_Between_Clinical_Phenotypes/links/61b359a04b318a6970cfc2ca/largepreview.png)
PDF) Erenumab for Migraine Prevention in a 1-Year Compassionate Use Program: Efficacy, Tolerability, and Differences Between Clinical Phenotypes
![FD26DE28-AC47-47B6-9C41-9167EEA79EDE_1_201_a.jpeg?w=372&h=372&org_if_sml=0&optipress=2&fit_enlarge=1&sharp=0 FD26DE28-AC47-47B6-9C41-9167EEA79EDE_1_201_a.jpeg?w=372&h=372&org_if_sml=0&optipress=2&fit_enlarge=1&sharp=0](https://prosteps.cloudimg.io/v7/https://tilroy.s3.eu-west-1.amazonaws.com/108/content/FD26DE28-AC47-47B6-9C41-9167EEA79EDE_1_201_a.jpeg?w=372&h=372&org_if_sml=0&optipress=2&fit_enlarge=1&sharp=0)